Healthcare is one of the most reliably essential sectors for dividend investors. Demand is non-cyclical — people do not defer cancer treatment during recessions. Pricing power is exceptional — pharmaceutical and medical device companies operate in markets where value is measured in lives, not price sensitivity. And the regulatory moats are high — FDA approval, patent protection, and clinical trial requirements create barriers that take a decade and billions of dollars to clear.
Johnson & Johnson (JNJ) and AbbVie (ABBV) are the two most discussed income investments in the sector. Both offer compelling dividend characteristics. Both have passed multiple market cycle tests. But they are built on fundamentally different business models, carry fundamentally different risk profiles, and serve fundamentally different functions in a dividend portfolio.
The Business Behind Each Dividend
Johnson & Johnson is the most diversified company in healthcare. Following the 2023 spinoff of Kenvue (the consumer health division that housed Band-Aid, Tylenol, and Neutrogena), JNJ is now a focused pharmaceutical and medical device company. The remaining business is higher-margin, more patent-protected, and arguably better positioned for the next decade of healthcare growth than the pre-spinoff conglomerate.
JNJ's pharmaceutical portfolio spans oncology (Darzalex, Carvykti, Erleada), immunology (Stelara, Tremfya), neuroscience, and infectious disease. The medical technology segment is a global leader in orthopedic implants, surgical robotics (Ottava, in development), electrophysiology, and vision care. No single drug represents more than 20% of total revenue — a level of diversification that most pure pharmaceutical companies cannot match.
The core JNJ investment thesis is predictability: a company with revenue spread across hundreds of drugs, devices, and procedures across 50+ countries that has raised its dividend for 62 consecutive years. Not despite the complexity of healthcare — because of how that complexity has been managed.
AbbVie is a fundamentally more concentrated bet. Spun off from Abbott Laboratories in 2013, ABBV was built around one of the most profitable drugs ever manufactured: Humira, a biologic treatment for rheumatoid arthritis and other autoimmune conditions that at peak generated more than $20 billion in annual revenue — roughly a quarter of its total, from a single drug.
The Humira patent expiration and the subsequent biosimilar competition that began in 2023 represents the central drama of AbbVie's dividend story. The company has spent a decade — and $30+ billion in acquisitions, most significantly Allergan in 2020 — building a successor portfolio designed to absorb the Humira revenue decline. That portfolio is centered on Skyrizi (for plaque psoriasis, Crohn's disease, and other inflammatory conditions) and Rinvoq (for rheumatoid arthritis and related autoimmune diseases), with Allergan contributing Botox and a diversified aesthetics and neurology business.
The early evidence suggests the transition is working. Skyrizi and Rinvoq have ramped faster than the most optimistic analyst forecasts. But "working so far" is not the same as "certain to succeed" — and the uncertainty is reflected in AbbVie's structurally higher yield.
Dividend History: 62 Years vs. 13 Years
The most stark difference between JNJ and ABBV as dividend stocks is the length and character of their tracks records.
Johnson & Johnson has raised its dividend for 62 consecutive years. That streak has survived: the Tylenol tampering crisis of 1982, multiple product liability lawsuits including talcum powder litigation, drug patent cliffs on previous blockbusters (Remicade, Procrit), the 2008 financial crisis, COVID, and the spinoff of its consumer division in 2023. Each of those events created periods of uncertainty — and in each case, the dividend continued to grow.
The 10-year compound dividend growth rate for JNJ has been approximately 6–7%. The payout ratio has remained in the 40–55% range throughout, conservative for a pharmaceutical company and reflective of management's commitment to building in financial cushion. The quality score on JNJ reflects maximum points for streak length, excellent marks for payout sustainability, and strong FCF coverage.
AbbVie's independent dividend history begins in 2013 — 13 years as of this writing. Within that period, ABBV has raised its dividend every year, and the 10-year compound growth rate has been extraordinary: approximately 12–15%, driven by Humira's cash generation during its peak years. The payout ratio has historically run 60–80% of GAAP earnings, though this figure is complicated by large non-cash amortization charges from the Allergan acquisition. On an adjusted free cash flow basis, coverage has been more comfortable than the GAAP number suggests.
What AbbVie's shorter streak does not capture is the pre-spinoff Abbott dividend history. Abbott had raised its dividend for 40+ consecutive years before the spinoff, and AbbVie inherited both the culture and the institutional investor base of a multi-decade dividend compounder. This context matters for interpretation even if quality scoring systems cannot directly incorporate it.
The Weiss Method Applied to Healthcare
Healthcare presents two distinct Weiss profiles depending on which company you are analyzing.
JNJ's yield history is tight and reliable, reflecting the stability premium the market assigns to a 62-year dividend compounder. The 10-year range has typically spanned approximately 2.3% to 3.4%. The median sits around 2.7–2.9%. Weiss undervalued signals on JNJ are meaningful precisely because they are uncommon — the stock rarely becomes cheap enough to trigger the signal. When it does, it is almost always during broad market selloffs rather than JNJ-specific problems. The 2022 rate-hike environment and occasional drug pipeline concerns have pushed JNJ toward undervalued territory — and both periods proved to be good entry points.
ABBV's yield history is wider and structurally higher, reflecting the premium yield the market demands for AbbVie's concentrated drug exposure and Humira transition risk. The 10-year range has spanned approximately 3.2% to 6.5%+, with the upper extreme reached when Humira patent expiration fears peaked. The median sits around 4.0–4.5%.
The Weiss signal fires more frequently on ABBV than on JNJ, and requires a different interpretation: some ABBV yield spikes reflect genuine uncertainty about dividend sustainability (the Humira transition was a real risk), not just cyclical cheapness. Investors need to assess whether the elevated yield reflects business stress or market over-reaction. During periods when the transition progress is clearly positive — Skyrizi and Rinvoq growth exceeding estimates — elevated yield represents an opportunity. During periods of genuine pipeline uncertainty, it may represent fair compensation for real risk.
Quality Score Analysis
Payout ratio: JNJ's 40–55% payout is conservative for a pharmaceutical company. ABBV's 60–80% GAAP payout is higher but adjusted FCF coverage is more comfortable. JNJ wins this factor.
Dividend streak: JNJ's 62-year streak earns maximum points on any quality scoring model. ABBV's 13-year independent streak earns fewer points. This is a known limitation of streak-based models applied to spinoffs — AbbVie's culture and investor base are clearly those of a long-term dividend compounder — but the scoring reflects what is objectively verifiable.
Dividend CAGR: ABBV wins on raw historical growth rate. The 12–15% 10-year CAGR reflects Humira's peak cash generation. The forward growth rate is likely to moderate as the business stabilizes post-transition, but should remain above JNJ's 6–7%.
FCF quality: JNJ's free cash flow is exceptionally predictable — diversified across hundreds of products and geographies. ABBV's FCF is higher-yielding but more concentrated, with meaningful sensitivity to the success of the Skyrizi/Rinvoq ramp. JNJ wins on predictability; ABBV wins on absolute FCF yield relative to market cap.
The Allergan Acquisition and Its Implications
AbbVie's 2020 acquisition of Allergan for $63 billion deserves specific attention because it permanently altered the dividend calculus.
The acquisition added Botox (both therapeutic and aesthetic), Restasis, Vraylar, and a diversified portfolio of specialty pharmaceuticals. It also added significant debt: ABBV's leverage ratio post-acquisition was meaningfully elevated, and debt reduction became a parallel priority alongside maintaining dividend growth.
The Botox franchise is particularly valuable because Botox Cosmetic operates in a cash-pay aesthetics market — it is not subject to insurance reimbursement pressure, formulary negotiations, or biosimilar competition in the same way as most pharmaceuticals. The therapeutic Botox business (treating migraine, overactive bladder, etc.) is similarly well-protected. Together they provide AbbVie with an earnings stream that has different risk characteristics than its immunology drugs.
The debt from the Allergan acquisition has been a constraint on dividend growth rate since 2020. As that debt is paid down — a process management has prioritized — the capacity for dividend growth will increase. Investors who bought ABBV during the high-debt, high-uncertainty period of 2020–2022 were rewarded both with high yields and with subsequent price appreciation as the transition thesis played out.
Which Belongs in Your Portfolio
Own Johnson & Johnson if you want the bedrock healthcare position in a dividend portfolio — 62 consecutive years of growth, exceptional diversification across drugs and medical devices, conservative payout ratios, and a post-Kenvue business focused on the highest-margin segments of healthcare. Accept a lower current yield (typically 2.5–3.5%) as the price of that stability and track record. JNJ is the anchor healthcare position that requires almost no monitoring once established at a fair or undervalued entry price.
Own AbbVie if you want a higher current yield (typically 3.5–5%+), have done the work to understand the post-Humira transition, and are comfortable with the execution risk that comes with any business that is managing a major revenue source declining while successor drugs ramp. ABBV rewards investors who can tolerate more volatility in exchange for significantly higher income. It is not a set-and-forget position the way JNJ is — it requires periodic monitoring of Skyrizi and Rinvoq ramp progress and pipeline developments.
The case for owning both is straightforward: they have completely different drug portfolios, different yield levels, and different risk profiles. Together they provide broad healthcare income exposure — JNJ as the stable low-yield anchor, ABBV as the higher-yield growth driver. For a dividend portfolio built for 15+ years, this combination has worked historically and the complementary risk profiles make it logical.
The healthcare sector is non-cyclical but not without risk — patent cliffs, regulatory decisions, and clinical trial outcomes can move individual stocks significantly. Diversifying across JNJ and ABBV within healthcare is a reasonable way to participate in the sector without overconcentrating in either company's specific risk profile.
Current Weiss signals and quality scores: JNJ analysis · ABBV analysis